Latest filing published 09 Sept 2026 for Vaxcyte, Inc., €371k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Andrew Guggenhime, listed as finance chief, appears in our data through filings on Vaxcyte, Inc. shares, published by SEC (Form 4). Over a trading history stretching from 18 November 2021 to 8 September 2026, the count stands at 53 filings.
Every open-market trade on record is a sale: 5 sales worth €968k. The totals exclude 1 filing filed without an amount. The rest of the record consists of 12 share grants and 35 option exercises. 2026 to date brings no purchases and 5 sales.
The newest entry dates from 9 September 2026: a share grant of €371k, in Vaxcyte, Inc. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 53 declarations